PPAR-delta as a Novel Therapeutic Target in Asthma

University Of Pittsburgh At Pittsburgh, Pittsburgh PA

Investigators

Linked publications & trials

Abstract

PROJECT SUMMARY Asthma affects >300 million people, with high morbidity and healthcare costs. Improved therapies are needed, because current therapies have adverse side effects and are ineffective in many patients. Asthma pathophysiology involves complex regulatory mechanisms in many different cell types, still little-understood at many levels. This research will test the role of a novel regulatory target in asthma, the orphan nuclear hormone receptor peroxisome proliferator-activated receptor ? (PPAR?). Based on preliminary findings that PPAR? acts within the lung to modulate asthma severity, we will determine if its dysregulation contributes to asthma, test feasibility of its therapeutic targeting, and elucidate key mechanisms. Airway epithelial cells (AECs) are important as both mediators and targets of asthma-related inflammation. Preliminary data suggest that PPAR? is downregulated in AECs of asthma patients and lungs of mice with allergic airway disease (AAD), and that globally downregulating PPAR? exacerbates AAD, whereas increasing PPAR? activity alleviates it. Our overall goal is to elucidate the role of PPAR? in regulating asthma severity and the mechanisms involved. The aims are: 1) to determine the mechanisms underlying induction of PPAR? ubiquitination and degradation by asthma- related cytokines and whether the resulting PPAR? deficiency exacerbates AAD pathogenesis and severity, comparing responses of wild-type AAD-bearing mice with those of novel strains having global or AEC-specific PPAR? deficiency; 2) to test whether treatment with novel PPAR? agonists blocks effects of asthma-related cytokines and agonist-induced or constitutive PPAR? activation ameliorates asthma severity specifically via AECs. These studies will exploit our novel resources including PPAR? KO mice lacking the fetal mortality that has hampered previous studies, a novel mouse strain expressing constitutively active PPAR? specifically in AECs, and PPAR? agonists we developed that are uniquely suited to administration by inhalation, preferred for asthma treatment. Taken together, our results will significantly advance understanding of PPAR? roles in lung biology and disease, and identify a new target for improved asthma therapy.